ReviewJournal of neural transmission (Vienna, Austria : 1996)2026
Neuromodulation of excitation-inhibition balance in dementia with lewy bodies: a translational framework.
Review in Journal of neural transmission (Vienna, Austria : 1996), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dementia with Lewy bodies (DLB) is a complex neurodegenerative disorder characterized by cognitive fluctuations, visual hallucinations, parkinsonism, mood disturbances and REM sleep behavioural disorder. Despite extensive research into its neuropathology, most notably the deposition of Lewy pathology and widespread neural loss, the mechanistic link between cellular pathology and clinical manifestations remains elusive. In this review, we propose a translational framework that focuses on the disruption of the excitation-inhibition (E/I) balance in large-scale networks, governed by the dysfunction of neuromodulatory systems. The dopaminergic, cholinergic, serotonergic, and noradrenergic systems, each affected in DLB, modulate excitatory and inhibitory signalling, synaptic plasticity, and large-scale neural dynamics. We synthesize evidence from molecular, neuroimaging, and clinical studies to support the notion that neuromodulatory impairment leads to E/I imbalance, contributing to altered brain connectivity and dysfunctional network states. These disruptions underlie key neuropsychiatric symptoms including cognitive deficits, hallucinations, and mood disturbances. Moreover, we discuss current and emerging pharmacologic strategies, targeting neurotransmitter receptors and synaptic excitability, that may restore E/I balance and improve symptom management. Finally, we highlight the role of neuromodulation in regulating brain states and propose that DLB symptoms emerge from dysfunction of network states, reflecting a failure of the neuromodulatory control. We also explore how risk factors, cognitive reserve, and disease progression affect compensatory capacity and the integrity of E/I homeostasis. This integrative model provides a mechanistic basis for understanding symptom emergence in DLB and offers a translational roadmap for novel therapeutic interventions.
Indexed as
Identifiers
41343057What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.